14 Schoolhouse Road
Somerset, NJ 08873
T: +1 (888) 765-8846

Catalent is the global leader in enabling pharmaceutical, biotechnology, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients globally.

With broad scale and deep expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Each year, Catalent helps accelerate over 1,500 partner programs, launches more than 150 new products, and supplies around 80 billion doses of nearly 8,000 products. Catalent’s global network comprises over 50 sites and an expert workforce of approximately 19,000, including over 3,000 scientists and technicians.

Technology Highlights

Catalent applies rigorous science, superior technologies, and deep expertise to improve its partners’ treatments and bring them through the clinic to patients, faster. Proactive investment and powerful partnerships help transform challenging molecules and new modalities into real treatments.

  • Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, as well as plasmid DNA. Catalent’s UpTempo VirtuosoTM AAV platform process provides early-stage clients with accelerated timelines for the production of their clinical material. Its comprehensive cell therapy portfolio includes expertise across multiple cell types including CAR-T, autologous and allogeneic cell therapy development and manufacturing, and human induced pluripotent stem cells (iPSCs);
  • Advanced GPEx® cell line expression technology for biopharmaceutical development, bioanalytics and biomanufacturing;
  • OptiForm® Solution Suite for rapid, optimized dose form development and bioavailability enhancement technologies, including lipid-based systems, spray drying technology, particle-size engineering, and the OptiMelt® hot melt extrusion (HME) platform;
  • Extensive and unique delivery technologies: including OptiShell® gelatin-free capsule technology; Zydis® orally disintegrating tablets; oral controlled release including OptiGel® DR; FlexDoseSM stick pack; SMARTag® technology for antibody-drug conjugates; and injectable forms.

Integrated Solutions

Catalent offers integrated development and product supply solutions that can be combined or tailored to enable customers to progress drugs, biologics, and consumer health products from laboratory to market, faster. Post-launch, Catalent provides comprehensive, integrated product supply, from sourcing bulk APIs through to manufacturing and packaging, release testing, and distribution. These flexible, scalable, and creative solutions meet the unique needs of partners of all sizes, from the smallest innovators to the largest pharmaceutical leaders and consumer health companies, advancing thousands of molecules through development towards commercial supply.

Headquartered in Somerset, NJ, the company generated nearly $5 billion in revenue in its 2022 fiscal year.

More products. Better treatments. Reliably supplied.TM